Phase 2 N=29 Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Phase 2 N=31 Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Phase 2 N=15 Nivolumab in AML in Remission at High Risk for Relapse
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Blasts Under 10 Percent of Bone Marrow Nucleated Cells
Primary: Recurrence-free Survival Rate — 8.5 Months
Phase 2 N=24 Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
Leukemia
Primary: Rate of Disease Free Survival at One Year — 50 percentage of participants
Phase 3 N=45 Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
Acute Myelogenous Leukemia
Primary: Number of Participants With Relapse-Free Response at 1 Year — 10; 10 participants
Phase 1 N=9 A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients
Acute Myeloid Leukemia
Primary: Occurrence of Dose Limiting Toxicities — 0; 0; 0 participants
Phase 2 N=12 A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
Acute Myeloid Leukemia
Primary: Time to Relapse (TTR) — 12.14 months
Phase 2 N=15 Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Phase 2 N=46 Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Phase 3 N=144 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Disease-free Survival — 8.87; 5.26 months — p=0.026
Phase 2 N=10 Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Phase 2 N=546 Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Acute Myeloid Leukemia · Acute Myeloid Leukemia With Myelodysplasia-Related Changes · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Primary: Number of Participants Who Completed Maintenance Decitabine. — 62 participants
Phase 2 N=40 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
AML
Primary: Complete Response Rate — 19 Participants
Phase 4 N=65 Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Leukemia
Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05
Phase 2 N=73 Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
N/A N=14 Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Phase 2 N=50 Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0 Participants
Phase 1 N=30 BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
Leukemia, Myeloid, Acute
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)
Phase 3 N=223 Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Leukemia, Myelocytic, Acute
Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559
Phase 3 N=472 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
Leukemia, Myeloid, Acute
Primary: Kaplan-Meier (K-M) Estimate for Overall Survival (OS) — 24.7; 14.8 Months — p=0.0009
Phase 2 N=20 Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Acute Myeloid Leukemia
Primary: Number of Patients With 2-year Relapse Risk — 10 Participants
Phase 3 N=105 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Leukemia
Primary: 3-year Disease-free Survival (DFS) Rate — 96; 100 percentage of patients
Phase 2 N=27 Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
N/A N=17 Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia · Adult Myelodysplastic Syndrome
Primary: Rate of Hospital Admission During Outpatient Induction Chemotherapy — 3; 14 Participants
Phase 2 N=36 Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Phase 2 N=175 Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
Leukemia · Acute Myeloid Leukemia · AML
Primary: Complete Response (CR) Rate — 98; 4; 9; 7 Participants
Phase 2 N=41 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
N/A N=610 Home Away From Home - Medical Outcomes
Acute Myeloid Leukemia · Neutropenia · Bacteremia
Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants
Phase 2 N=55 Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Complete Response = Morphologic Complete Remission (mCR) — 13 Participants